Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREND: Erlotinib and Radiotherapy in EGFR-mutant Locally Advanced NSCLC
NCT03074864Phase 3Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03074864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03074864.